KIF1A-related autosomal dominant spastic paraplegias (SPG30) in Russian families.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
03 Aug 2020
Historique:
received: 24 04 2020
accepted: 28 07 2020
entrez: 5 8 2020
pubmed: 5 8 2020
medline: 11 11 2020
Statut: epublish

Résumé

Spastic paraplegia type 30 (SPG30) caused by KIF1A mutations was first reported in 2011 and was initially considered a very rare autosomal recessive (AR) form. In the last years, thanks to the development of massive parallel sequencing, SPG30 proved to be a rather common autosomal dominant (AD) form of familial or sporadic spastic paraplegia (SPG),, with a wide range of phenotypes: pure and complicated. The aim of our study is to detect AD SPG30 cases and to examine their molecular and clinical characteristics for the first time in the Russian population. Clinical, genealogical and molecular methods were used. Molecular methods included massive parallel sequencing (MPS) of custom panel 'spastic paraplegias' with 62 target genes complemented by familial Sanger sequencing. One case was detected by the whole -exome sequencing. AD SPG30 was detected in 10 unrelated families, making it the 3rd (8.4%) most common SPG form in the cohort of 118 families. No AR SPG30 cases were detected. In total, 9 heterozygous KIF1A mutations were detected, with 4 novel and 5 known mutations. All the mutations were located within KIF1A motor domain. Six cases had pure phenotypes, of which 5 were familial, where 2 familial cases demonstrated incomplete penetrance, early onset and slow relatively benign SPG course. All 4 complicated cases were caused by novel mutations without familial history. The phenotypes varied from severe in two patients (e.g. lack of walking, pronounced mental retardation) to relatively mild non-disabling symptoms in two others. AD SPG30 is one of the most common forms of SPG in Russia, the disorder has pronounced clinical variability while pure familial cases represent a significant part.

Sections du résumé

BACKGROUND BACKGROUND
Spastic paraplegia type 30 (SPG30) caused by KIF1A mutations was first reported in 2011 and was initially considered a very rare autosomal recessive (AR) form. In the last years, thanks to the development of massive parallel sequencing, SPG30 proved to be a rather common autosomal dominant (AD) form of familial or sporadic spastic paraplegia (SPG),, with a wide range of phenotypes: pure and complicated. The aim of our study is to detect AD SPG30 cases and to examine their molecular and clinical characteristics for the first time in the Russian population.
METHODS METHODS
Clinical, genealogical and molecular methods were used. Molecular methods included massive parallel sequencing (MPS) of custom panel 'spastic paraplegias' with 62 target genes complemented by familial Sanger sequencing. One case was detected by the whole -exome sequencing.
RESULTS RESULTS
AD SPG30 was detected in 10 unrelated families, making it the 3rd (8.4%) most common SPG form in the cohort of 118 families. No AR SPG30 cases were detected. In total, 9 heterozygous KIF1A mutations were detected, with 4 novel and 5 known mutations. All the mutations were located within KIF1A motor domain. Six cases had pure phenotypes, of which 5 were familial, where 2 familial cases demonstrated incomplete penetrance, early onset and slow relatively benign SPG course. All 4 complicated cases were caused by novel mutations without familial history. The phenotypes varied from severe in two patients (e.g. lack of walking, pronounced mental retardation) to relatively mild non-disabling symptoms in two others.
CONCLUSION CONCLUSIONS
AD SPG30 is one of the most common forms of SPG in Russia, the disorder has pronounced clinical variability while pure familial cases represent a significant part.

Identifiants

pubmed: 32746806
doi: 10.1186/s12883-020-01872-4
pii: 10.1186/s12883-020-01872-4
pmc: PMC7398351
doi:

Substances chimiques

KIF1A protein, human 0
Kinesins EC 3.6.4.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

290

Références

PLoS One. 2017 Mar 31;12(3):e0174667
pubmed: 28362824
Neurologia. 2019 Mar 9;:
pubmed: 30862385
Front Genet. 2020 Feb 27;11:61
pubmed: 32174959
Eur J Hum Genet. 2020 Jan;28(1):40-49
pubmed: 31488895
Front Neurol. 2018 Dec 04;9:981
pubmed: 30564185
Eur J Hum Genet. 2015 Oct;23(10):1427-30
pubmed: 25585697
Am J Hum Genet. 2011 Mar 11;88(3):306-16
pubmed: 21376300
Ann Clin Transl Neurol. 2015 Jun;2(6):623-35
pubmed: 26125038
Eur J Hum Genet. 2012 Jun;20(6):645-9
pubmed: 22258533
J Clin Neurosci. 2019 Mar;61:298-301
pubmed: 30385166
Neuropediatrics. 2020 Apr;51(2):146-153
pubmed: 31805580
Front Cell Neurosci. 2019 Sep 26;13:419
pubmed: 31616253
Brain. 2006 Jun;129(Pt 6):1456-62
pubmed: 16434418
Eur J Hum Genet. 2016 Jun;24(6):949-53
pubmed: 26486474
J Peripher Nerv Syst. 2020 Jun;25(2):117-124
pubmed: 32096284
Eur J Neurol. 2017 May;24(5):741-747
pubmed: 28332297
Mol Genet Genomic Med. 2019 Nov;7(11):e968
pubmed: 31512412
J Child Neurol. 2016 Aug;31(9):1114-9
pubmed: 27034427
Hum Mutat. 2015 Jan;36(1):69-78
pubmed: 25265257
J Mol Med (Berl). 2018 Jul;96(7):701-712
pubmed: 29934652
Sci Rep. 2017 Oct 2;7(1):12527
pubmed: 28970574
Intern Med. 2020 Mar 15;59(6):839-842
pubmed: 31813911
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Hum Genet. 2014 Nov;59(11):639-41
pubmed: 25253658
eNeurologicalSci. 2018 Nov 22;14:34-37
pubmed: 30582020
Genome Res. 2011 May;21(5):658-64
pubmed: 21487076
Am J Hum Genet. 2011 Aug 12;89(2):219-30
pubmed: 21820098
Ital J Pediatr. 2019 Dec 3;45(1):155
pubmed: 31796088
Epilepsy Res. 2019 Oct;156:106181
pubmed: 31394400
J Peripher Nerv Syst. 2017 Dec;22(4):460-463
pubmed: 28834584
J Neurol. 2015 Dec;262(12):2684-90
pubmed: 26410750
Eur J Hum Genet. 2016 Oct;24(10):1460-6
pubmed: 27165006
Ann Clin Transl Neurol. 2017 Oct 14;4(11):821-824
pubmed: 29159194
Can J Ophthalmol. 2017 Oct;52(5):e169-e171
pubmed: 28985824
Neurogenetics. 2019 Mar;20(1):27-38
pubmed: 30778698
J Hum Genet. 2015 Dec;60(12):739-42
pubmed: 26354034
Eur J Hum Genet. 2017 Nov;25(11):1217-1228
pubmed: 28832565

Auteurs

G E Rudenskaya (GE)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

V A Kadnikova (VA)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia. vkadnikova@gmail.com.

O P Ryzhkova (OP)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

L A Bessonova (LA)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

E L Dadali (EL)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

D S Guseva (DS)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

T V Markova (TV)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

D N Khmelkova (DN)

"Genomed" Ltd, Moscow, Russia.

A V Polyakov (AV)

Federal State Budgetary Scientific Institution "Research Centre for Medical Genetics" (RCMG), Moscow, Russia.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH